The Regulator submits quarterly reports on its performance and activities to the Executive Authority as mandated by the Medicines and Related Substances Act (1965, as amended) and the PFMA (1999, as amended). In addition, the Executive Authority was briefed on three critical matters:

  • SAHPRA’s progress on the registration of COVID-19 vaccines. There were a few engagements that culminated in SAHPRA’s participation in various COVID-19 structures.
  • SAHPRA’s position on Ivermectin. This matter led to litigation against the Minister and the Regulator and reports in this regard were submitted to the Executive Authority.
  • SAHPRA’s position on cannabis. Various reports were submitted to the Executive Authority on the activities of SAHPRA together with its narrow mandate on medicinal cannabis.